JP2014515400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515400A5 JP2014515400A5 JP2014513502A JP2014513502A JP2014515400A5 JP 2014515400 A5 JP2014515400 A5 JP 2014515400A5 JP 2014513502 A JP2014513502 A JP 2014513502A JP 2014513502 A JP2014513502 A JP 2014513502A JP 2014515400 A5 JP2014515400 A5 JP 2014515400A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- vasoconstrictor
- acid salt
- skin
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 20
- 238000009472 formulation Methods 0.000 claims 19
- 239000005526 vasoconstrictor agent Substances 0.000 claims 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 230000001800 adrenalinergic effect Effects 0.000 claims 4
- 239000003960 organic solvent Substances 0.000 claims 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 2
- -1 tetrahydrozaline Natural products 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical group CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- 229960005192 methoxamine Drugs 0.000 claims 1
- 229960005016 naphazoline Drugs 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- 229960001802 phenylephrine Drugs 0.000 claims 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 229960001360 zolmitriptan Drugs 0.000 claims 1
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161492664P | 2011-06-02 | 2011-06-02 | |
| US61/492,664 | 2011-06-02 | ||
| PCT/US2012/028446 WO2012166227A1 (en) | 2011-06-02 | 2012-03-09 | Formulation of small adrenergic agonist salt forms in organic solvents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014515400A JP2014515400A (ja) | 2014-06-30 |
| JP2014515400A5 true JP2014515400A5 (enExample) | 2015-04-30 |
Family
ID=47259712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513502A Pending JP2014515400A (ja) | 2011-06-02 | 2012-03-09 | 有機溶媒中に形成された式量の小さいアドレナリン作動薬塩の製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140343159A1 (enExample) |
| EP (1) | EP2713988A4 (enExample) |
| JP (1) | JP2014515400A (enExample) |
| CN (1) | CN103764100A (enExample) |
| AU (1) | AU2012262947A1 (enExample) |
| WO (1) | WO2012166227A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2770731T3 (es) | 2014-08-28 | 2020-07-02 | Sun Pharmaceutical Ind Ltd | Forma de dosificación parenteral de norepinefrina |
| EP3319607A4 (en) | 2015-07-09 | 2019-04-03 | Galderma S.A. | METHOD FOR REDUCING HAIR LOSS IN CONNECTION WITH CHEMOTHERAPY |
| CN113453663B (zh) * | 2019-01-10 | 2024-07-05 | 太阳医药工业有限公司 | 稳定的可注射肾上腺素水溶液 |
| AU2022443966A1 (en) * | 2022-03-04 | 2024-08-22 | Vasodynamics Limited | Topical compositions and methods. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4643586A (en) * | 1983-01-12 | 1987-02-17 | Hansen Jens S | Equipment and method for calibration of instruments having a temperature sensing unit |
| CA2154979A1 (en) * | 1995-07-28 | 1997-01-29 | Kenneth T. Armstrong | Topical phenylephrine preparation |
| US7405080B2 (en) * | 2000-03-23 | 2008-07-29 | Voellmy Richard W | Compositions and methods relating to prevention of chemotherapy-induced alopecia |
| US7229630B2 (en) * | 2002-06-20 | 2007-06-12 | Novalar Pharmaceuticals, Inc. | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
| AU2006261358B2 (en) * | 2005-06-17 | 2012-05-31 | Wisconsin Alumni Research Foundation | Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy |
| CA2645073A1 (en) * | 2006-03-08 | 2007-09-13 | Nuviance, Inc. | Transdermal drug delivery compositions and topical compositions for application on the skin |
| WO2010001391A1 (en) * | 2008-06-30 | 2010-01-07 | Oron Zachar | Dermal application of vasoconstrictors |
| US8969331B2 (en) * | 2008-10-01 | 2015-03-03 | Roman Kelner | Treatment of skin and mucosal superficial wounds using adrenergic receptor agonists |
-
2012
- 2012-03-09 US US14/122,442 patent/US20140343159A1/en not_active Abandoned
- 2012-03-09 WO PCT/US2012/028446 patent/WO2012166227A1/en not_active Ceased
- 2012-03-09 JP JP2014513502A patent/JP2014515400A/ja active Pending
- 2012-03-09 EP EP12792555.0A patent/EP2713988A4/en not_active Withdrawn
- 2012-03-09 AU AU2012262947A patent/AU2012262947A1/en not_active Abandoned
- 2012-03-09 CN CN201280036959.XA patent/CN103764100A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016155880A5 (enExample) | ||
| JP2013538853A5 (enExample) | ||
| JP2014515400A5 (enExample) | ||
| CA2864118A1 (en) | Formulations of bendamustine | |
| WO2012015810A3 (en) | Pharmaceutical compositions containing pemetrexed having extended storage stability | |
| JP2013509429A5 (enExample) | ||
| JP2012505171A5 (enExample) | ||
| PE20140960A1 (es) | Formulaciones que comprenden un inhibidor de dpp4 | |
| RU2016129490A (ru) | Композиции в виде геля для местного применения, включающие сополимер моностеароил-глицерина и сукцината, и способы повышения эффективности местного применения полезного средства | |
| MX346879B (es) | Formulaciones de ketorolaco listas para su uso. | |
| UY31672A1 (es) | "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación" | |
| WO2007117581A3 (en) | Stabilized transdermal bupropion preparations | |
| RU2015137145A (ru) | Новые жидкие композиции с повышенной стабильностью | |
| US11382978B2 (en) | Percutaneous absorption composition | |
| JP2016512246A5 (enExample) | ||
| RU2015102772A (ru) | Бензодиазелипы для мелкоклеточного рака легкого | |
| RU2012124904A (ru) | КОМБИНАЦИЯ АГОНИСТА α2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ И НЕСТЕРОИДНОГО ПРОТИВОВОСПАЛИТЕЛЬНОГО СРЕДСТВА ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ВОСПАЛИТЕЛЬНОГО ПОРАЖЕНИЯ КОЖИ | |
| RU2011140574A (ru) | Способ растворения противогрибкового средства и композиции с высокой концентрацией противогрибкового средства, подходящие для нанесения на ногти | |
| CL2014003081A1 (es) | Una composicion farmaceutica topica que comprende, en base al peso total de la composicion, 1,5-5 % en peso de terbinafina, 15-35 % en peso de urea y mas que 25 % en peso de agua; y su uso para el tratamiento topico de una infeccion fungica, preferiblemente onicomicosis. | |
| WO2014178789A9 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
| KR20180039622A (ko) | 경피 흡수 조성물 | |
| JP2014530847A5 (enExample) | ||
| AR085273A1 (es) | Formulacion liquida libre de propelente que comprende una droga antimuscarinica | |
| RU2014119919A (ru) | Способ лечения капиллярных гемангиом | |
| JP2014515400A (ja) | 有機溶媒中に形成された式量の小さいアドレナリン作動薬塩の製剤 |